Objective To evaluate the efficacy of Daunorubicin(DNR)+Arabinsyl cytosine(Ara-C)in patients with acute myeloid leukemia(AML).Methods A total of 80 AML patients admitted to the Affiliated Hospital of Zunyi Medical Univer-sity from January 2020 to December 2023 were selected as the study objects,and they were divided into control group(40 cases)and observation group(40 cases)according to random number table method.Control group was treated with DNR,ob-servation group was treated with DNR+Ara-C.The clinical effective rate,immune function,vascular endothelial growth fac-tor(VEGF),basic fibroblast growth factor(bFGF),soluble vascular cell adhesion molecule-1(sVCAM-1),soluble intercel-lular adhesion molecule-1(sICAM-1)and adverse reactions were compared between the two groups.Results The total clin-ical effective rate of the observation group was higher than that of the control group,and the difference was statistically sig-nificant(P＜0.05).After treatment,the levels of CD8+,VEGF,bFGF,sVCAM-1 and sICAM-1 in observation group were lower than those in control group,and the levels of CD4+and CD3+were higher than those in control group,with statistical significances(P＜0.05).There was no significant difference in adverse reactions between the two groups(P＞0.05).Con-clusion DNR+Ara-C in AML patients can reduce VEGF,bFGF,sVCAM-1,sICAM-1,alleviate immunosuppression,im-prove clinical efficiency,good safety,and have clinical reference significance.
维普
万方数据